Cognition Therapeutics, Inc. (CGTX): Price to Sales
The reliability of Cognition Therapeutics (CGTX) is based on the validation of oral drugs to combat brain degeneration and grant support. The company's market cap-to-revenue ratio, provided by the GURU.Markets platform, confirms the asset's dynamics, with the current level sitting around . The business advantage lies in synapse restoration, while the primary risk remains the success of clinical trials given the existing liquidity reserve.
Analytical breakdowns for Cognition Therapeutics (CGTX)
- price and consensus price forecast:
- stock exchange capitalization data:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Capital Cognition Therapeutics|CGTX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Cognition Therapeutics, Inc.|CGTX - Company Aggregate Debts|Debts to Book Value Cognition Therapeutics|CGTX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Cognition Therapeutics|Quick Ratio cogrx.com
- net income and valuation multiples indicators:
CGTX - Company Net Income|Forward Earnings Cognition Therapeutics|CGTX - P/E Multiple|Projected Price to Earnings Ratio Cognition Therapeutics, Inc.|CGTX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Cognition Therapeutics, Inc.|CGTX - Operating profit before deduction of amortization|Earnings per share for the last four quarters Cognition Therapeutics|CGTX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months cogrx.com|CGTX - Earnings growth in current year|Expected earnings per share growth for next year Cognition Therapeutics
- sales revenue and business income indicators:
General company analysis:CGTX - cogrx.com
To minimize risks when establishing a long-term position, it is essential to analyze the price-to-sales ratio, which reflects the premium paid for every dollar of revenue. The current P/S valuation for Cognition Therapeutics (CGTX) demonstrates that the business value depends on the success of clinical trials for target molecules and FDA approval, determining the company's resilience within the neurodegenerative disease sector.
Competitors of Cognition Therapeutics
BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Biosciences|Biohaven Ltd - Market Cap to Revenue|P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Market Cap to Revenue|Price-to-Revenue Coefficient Praxis Corp PRAX|AVXL: P/S Multiple|CBLL (ceribell.com) - Price-to-Revenue Ratio|PRTA (Prothena Corporation) - P/S Multiple|Market Cap to Revenue alector.com (ALEC)|Price-to-Revenue Ratio Annexon, Inc. (ANNX)|OMER - Price to Sales|P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Price to Sales|Voyager Therapeutics Inc - P/S Multiple|Neumora (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|TVGN - Price-to-Revenue Coefficient|ACOG (Alpha Cognition Inc) - P/S Multiple|Market Cap to Revenue inhibikase.com (IKT)|Price-to-Revenue Ratio Cassava Sciences Inc (SAVA)|Price-to-Revenue Coefficient Assertio|P/S Multiple COYA (Coya Therapeutics, Inc.)|Market Cap to Sales Volume VTGN (VistaGen Therapeutics Inc)|OVID: Market Cap to Revenue|ABOS: Price-to-Revenue Ratio|CervoMed (CRVO) - Price-to-Revenue Ratio|Price to Sales Alterity Therapeutics Ltd (ATHE)|CLNN (Clene) - P/S Multiple|Market Cap to Revenue Ratio PEPG (PepGen)|Market Cap to Revenue JUNS (Jupiter Neurosciences, Inc.)|P/S Multiple relmada.com (RLMD)|Price-to-Revenue Ratio Annovis Bio Corp ANVS|GRCE: Market Cap to Revenue Ratio|AIFF - Price-to-Revenue Ratio|KLTO (anewmeds.com) - Market Cap to Revenue Ratio|NRSN (NeuroSense Therapeutics Ltd.) - Market Cap to Revenue|revivapharma.com - Market Capitalization-to-Revenue Ratio|MTVA (metaviatx.com) - P/S Multiple|NRXS: Market Capitalization-to-Revenue Ratio|P/S Multiple HSDT|PASG - Price to Sales|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV: Market Cap to Revenue Ratio|ATHA: Market Cap to Revenue|Addex Therapeutics Ltd - Market Cap to Sales Volume|Alzamend Neuro, Inc. (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue PTIX|KTTA: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Market Capitalization-to-Revenue Ratio CARA|chromocell.com - P/S Multiple|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue
